ONE OF BIOHK2022'S LASTING TOPICS PHARMA AND DRUG DEVELOPMENT 香港国际生物科技展的持久话题之一 制药和药物研发 ONE OF BIOHK2022'S MANY TOPICS PHARMA AND DRUG DEVELOPMENT 香港国际生物科技展的多个话题之一 制药和药物研发 IDEAL PLACE 理想地方 As a fundamental part of treating diseases Pharma and New Drug Development is a topic that never goes out of date. The biotechnology industry accounts for approximately half of the scientifically innovative drugs approved and has further led to the discovery of drugs able to meet previously unmet medical needs. The pharma and biotech industry is constantly looking for better solutions against diseases, discovering new drug targets, repurposing existing drugs on the market, improving drug design and modelling, streamlining processes in drug development and commercialisation. With the advancements in technology provided by the biotech industry the pharma industry will experience an exponential increase in efficiency and production, advances in research and development as well as cost effective and less labour intensive solutions. 作为治疗疾病的关键部分,药物和新药开发是一个永不过时的话题。 生物科技行业在已批准的创新药物中约占一半,并让我们发现能够满足以前未满足的医疗需求的药物。 制药和生物科技行业一直在寻找更好的疾病解决方案,发现新的药物靶标,重新定位市场上的现有药物,改善药物设计和建模,简化药物开发和商业化过程。 随着生物科技行业提供的技术进步,制药业将经历效率和产量的指数增长,研究与开发的进步以及具有成本效益和劳动强度小的解决方案。 IMPORTANT 重要 At BIOHK2022 we bring in key international and local representatives in the pharma and biotechnology industry to discuss breakthroughs in drug development and discovery, current pharmaceutical supply chains, evaluate and provide updates on regulations, policies and registration requirements, applications of AI, big data analytics, robotics in drug development. Come together to accelerate the success of the drug development industry, providing solutions to problems that are yet to be discovered. 在香港国际生物科技展,我们邀请制药和生物科技行业的主要国际和本地代表参加,讨论药物开发和发现方面的突破,当前的药物供应链,评估并提供法规,政策和注册要求,人工智能的应用,大数据分析, 药物开发中的机器人技术。齐心协力,加速药物开发行业的成功,为尚未发现的问题提供解决方案。 IDEAL PLACE 理想地方 As a fundamental part of treating diseases Pharma and New Drug Development is a topic that never goes out of date. The biotechnology industry accounts for approximately half of the scientifically innovative drugs approved and has further led to the discovery of drugs able to meet previously unmet medical needs. The pharma and biotech industry is constantly looking for better solutions against diseases, discovering new drug targets, repurposing existing drugs on the market, improving drug design and modelling, streamlining processes in drug development and commercialisation. With the advancements in technology provided by the biotech industry the pharma industry will experience an exponential increase in efficiency and production, advances in research and development as well as cost effective and less labour intensive solutions. 作为治疗疾病的关键部分,药物和新药开发是一个永不过时的话题。 生物科技行业在已批准的创新药物中约占一半,并让我们发现能够满足以前未满足的医疗需求的药物。 制药和生物科技行业一直在寻找更好的疾病解决方案,发现新的药物靶标,重新定位市场上的现有药物,改善药物设计和建模,简化药物开发和商业化过程。 随着生物科技行业提供的技术进步,制药业将经历效率和产量的指数增长,研究与开发的进步以及具有成本效益和劳动强度小的解决方案。 IMPORTANT 重要 At BIOHK2022 we bring in international and local key representatives of the Pharma and biotechnology industry to discuss breakthroughs in drug development and discovery, current pharmaceutical supply chains, evaluate and provide updates on regulations, policies and registration requirements, applications of AI, big data analytics, robotics in drug development. Come together to accelerate the success of the drug development industry, providing solutions to problems that are yet to be discovered. 在香港国际生物科技展,我们邀请制药和生物科技行业的主要国际和本地代表参加,讨论药物开发和发现方面的突破,当前的药物供应链,评估并提供法规,政策和注册要求,人工智能的应用,大数据分析, 药物开发中的机器人技术。齐心协力,加速药物开发行业的成功,为尚未发现的问题提供解决方案。 CALLING FOR NEW CONFERENCE TOPICS AND SPEAKERS 呼吁新学术演讲题目及嘉宾 ! We are always on the lookout for new conference topics and speakers! If there is a topic that you would like us to feature, or someone you know who would make an excellent addition to our event, feel free to let us know. 我们一直寻找新的学术演讲题目及嘉宾!如果您认识某个精彩的题目或您身边认识一位出色的演讲嘉宾,请随时联络我们以作提名。 TOPICS 题目 TOPICS 题目 NATIONAL AND INTERNATIONAL DRUG RESEARCH AND DEVELOPMENT INDUSTRY IN FACILITATING ADDITIONAL USE OF DRUGS FOR THE GLOBAL COMMUNITY 国家和国际药物研究和行业开发,以促进国际社会更多地使用药物 Particular focus on Hong Kong – drug repurposing and repositioning 特别关注香港 - 药物的再利用和重新定位 NATIONAL AND INTERNATIONAL DRUG RESEARCH AND DEVELOPMENT INDUSTRY IN FACILITATING ADDITIONAL USE OF DRUGS FOR THE GLOBAL COMMUNITY 国家和国际药物研究和行业开发,以促进国际社会更多地使用药物 Particular focus on Hong Kong – drug repurposing and repositioning 特别关注香港 - 药物的再利用和重新定位 01 DRUG REPURPOSING RESEARCH IN HONG KONG (WORLD RENOWNED CASE STUDIES IN HONG KONG) 香港的药物再利用研究(香港的流行案例研究) Exhibiting Hong Kong’s world recognition in drug development 展示香港在药物研发方面的世界认可 02 THE ROLE OF REPURPOSED DRUGS IN HONG KONG TO TREAT CHRONIC DISEASES AND EMERGING INFECTIOUS DISEASES (ONCOLOGY, HEPATOLOGY, CARDIOVASCULAR DISEASES AND COVID-19) 药物在香港对治疗慢性病和新兴传染病(肿瘤,肝病,心血管疾病和2019新型冠状病毒病)的作用 03 COLLABORATION EFFORTS BETWEEN INTERNATIONAL DRUG DISCOVERY INDUSTRY AND HONG KONG’S DRUG DEVELOPMENT INDUSTRY 国际药物发现业与香港药物发展业之间的合作努力 Hong Kong is a big adopter of drugs registered in the U.S. and Europe, and Hong Kong further contributes to the global Pharma industry by researching the repurposing and repositioning of drugs, facilitating better use of current drugs in the market 香港是在美国和欧洲注册的毒品的主要采用国,并且香港通过研究毒品的再利用和重新定位,促进更好地在市场上使用现有药物来为全球制药业做出贡献 04 INCREASING COMMERCIALISATION ON PRESENT DRUGS 增加当前药物的商业化 05 POST MARKETING CLINICAL TRIALS, REPOSITIONING OF DRUGS 营销后临床试验,药物重新定位 06 HOW HONG KONG CAN LEVERAGE PHARMA AND DRUG DEVELOPMENT 香港如何利用制药和药物开发 07 GAINING GBA'S POV IN DRUG DEVELOPMENT, HOW WE CAN UTILISE THE CONNECTIONS WE HAVE WITH GBA TO FURTHER COMMERCIALISE PRODUCTS 在药物开发中获得大湾区的观点,我们如何利用与大湾区的联系来进一步商品化 HONG KONG’S CURRENT STAGE IN THE DRUG DEVELOPMENT INDUSTRY 香港现阶段的药物开发行业 HONG KONG’S CURRENT STAGE IN THE DRUG DEVELOPMENT INDUSTRY 香港现阶段的药物开发行业 01 HONG KONG’S POSITION IN THE DRUG DEVELOPMENT AND PHARMA INDUSTRY 香港在药物开发和制药行业中的地位 02 WHERE HONG KONG'S STRENGTH AND WEAKNESSES ARE IN DRUG DEVELOPMENT 药物发展中香港的实力和弱点在哪里 03 WHAT AREAS IN DRUG DEVELOPMENT DO WE NEED TO FURTHER ACCELERATE? 我们需要进一步加快药物开发的哪些领域? 04 ACCOMPLISHMENTS IN THE DRUG DEVELOPMENT INDUSTRY (CASE STUDY) 药物开发行业的成就(案例研究) 05 DIRECTION OF CURRENT RESEARCH 当前研究方向 06 POLICIES AND REGULATIONS REGARDING DRUG DEVELOPMENT IN HONG KONG (I.E. CLINICAL TRIALS, SUPPLY CHAIN, PATENTS) 关于香港药物发展的政策和法规(即临床试验,供应链,专利) INVESTIGATING NOVEL DRUG DESIGN AND NEW DRUG DEVELOPMENT 研究新型药物设计和新药物开发 INVESTIGATING NOVEL DRUG DESIGN AND NEW DRUG DEVELOPMENT 研究新型药物设计和新药物开发 01 GPCR TARGETED DRUG DESIGN G蛋白偶联受体靶向药物设计 02 MOLECULAR MODELLING 分子模拟 03 PROTEIN – PROTEIN INTERACTIONS 蛋白质–蛋白质相互作用 04 BIOPHYSICAL APPROACHES FOR DRUG DISCOVERY 药物发现的生物物理方法 05 FRAGMENT BASED DRUG DISCOVERY 基于碎片的药物发现 06 MACROCYCLIC AND CONSTRAINED PEPTIDES 大环肽和约束肽 07 DRUG TARGET INTERACTIONS 药物目标相互作用 08 RARE DISEASES RESEARCH IN DRIVING SCIENTIFIC BREAKTHROUGHS TO ENABLE NEW DRUG DISCOVERY AND DEVELOPMENT 推动科学突破以实现新的药物发现和发展的罕见病研究 09 DRUGS AS ANTIVIRALS 药物作为抗病毒药 10 DRUG COMBINATION THERAPY 药物联合治疗 DEVELOPING THE INFRASTRUCTURE OF THE DRUG DEVELOPMENT INDUSTRY 发展药物开发产业的基础设施 DEVELOPING THE INFRASTRUCTURE OF THE DRUG DEVELOPMENT INDUSTRY 发展药物开发产业的基础设施 01 CLINICAL TRIALS INFRASTRUCTURE 临床试验基础设施 i) Collaborative research opportunities in China
i) 在中国的合作研究机会
(海外代表和本地代表之间建立论坛,讨论香港在哪里可以进一步发展我们的基础设施以及我们可以从海外行业领袖那里学到什么) 02 DO WE HAVE THE CORRECT INFRASTRUCTURE TO ACCELERATE DRUG DEVELOPMENT EFFORTS? 我们是否拥有正确的基础设施来加速药物开发工作? Facilities and resources to conduct clinical trials, registration of drugs 进行临床试验,药品注册的设施和资源 03 DO WE HAVE THE FACILITIES AND RESOURCES AVAILABLE TO DO SO? (I.E. TO CONDUCT CLINICAL TRIALS, REGISTRATION OF DRUGS) 我们是否有可用的设施和资源?(即进行临床试验,药品注册) 04 TALENT RECRUITMENT EFFORTS 人才招聘 05 HOW LONG WOULD IT TAKE FOR US TO REACH A DESIRED POSITION IN THE PHARMA / DRUG DEVELOPMENT INDUSTRY? 我们要花多长时间才能在制药/药物开发行业中达到理想的位置? 06 FURTHERING THE COMMERCIALISATION OF EXISTING PRODUCTS 促进现有产品的商业化 i) Pharmaceutical and patent strategy and drug repositioning with solid forms ii) Key business and IP considerations for furthering drug repurposing programs i) 药物和专利策略以及实体形式的药物重新定位 ii) 推进药物再利用计划的关键业务和知识产权注意事项 BIG DATA, ANALYTICS, MACHINE LEARNING AND AI IN RESEARCH AND COMMERCIALISATION OF DRUGS 药物研究与商业化中的大数据,分析,机器学习和人工智能 BIG DATA, ANALYTICS, MACHINE LEARNING AND AI IN RESEARCH AND COMMERCIALISATION OF DRUGS 药物研究与商业化中的大数据,分析,机器学习和人工智能 01 ANALYSING DRUG EFFICACY 分析药物功效 02 ENHANCING COMMERCIALISATION OF DRUGS 加强药物的商业化 03 PROVIDING ECONOMIC MODELS TO COMBINE PROVISION OF DRUGS AND SERVICES 提供经济模型来组合药物和服务的提供 04 AI IN INVESTIGATING THE PHARMACOLOGY OF DRUGS E.G. DRUG INTERACTION MODELS 人工智能在研究药物的药理学方面例如药物相互作用模型 05 PAT SYSTEMS IN ANALYSING ON GOING PROCESSES, PREDICTING RESPONSES AND PROVIDING SIMULATION OF DRUG INTERACTIONS PAT(过程分析技术)系统,用于分析进行中的过程,预测反应并提供药物相互作用的模拟 06 AUTOMATED MANUFACTURING AND TESTING OF DRUGS 药物的自动化生产和测试 07 COMPOUND SCREENING FOR DRUG DEVELOPMENT 药物开发的复合筛选 08 INVESTIGATING POTENTIAL DRUG TARGETS 调查潜在药物目标 09 INNOVATIVE DRUG RESEARCH AND TECHNOLOGY PLATFORM 创新药物研究与技术平台 10 BIOSTATICS AND BIOINFORMATICS FOR DRUG DEVELOPMENT 药物开发的生物统计学和生物信息学 i) Genomics and Proteomics i) 基因组学和蛋白质组学 ...... AND MORE ...... 及更多 ...... AND MORE ...... 及更多 BIOHK2022 is the first international biotech convention to be held in Hong Kong and one of the first face-to-face meetings after COVID-19 for all to enjoy. BIOHK will present an exceptional international biotech kaleidoscope event to you. 香港国际生物科技展是首个在香港举行的国际生物科技展,也是2019新型冠状病毒病爆发之后第一批线下会议之一。 BIOHK将为您呈现一场国际生物科技万花筒盛会。 Copyright © 2020 Hong Kong Biotechnology Organisation. All rights reserved. Changed your mind? You can unsubscribe at any time.
版权所有 © 2020 香港生物科技协会 不再想要接收这些电子邮件? 按此退订 |